Core Viewpoint - The stock of Yiming Oncology-B (01541) has increased by over 6%, currently trading at 15.15 HKD with a transaction volume of 45.67 million HKD, following the announcement of new clinical trial applications for its drug IMM2510 [1] Group 1: Clinical Developments - Yiming Oncology has submitted an application to the National Medical Products Administration for a Phase III clinical trial of IMM2510, aimed at treating immune therapy-resistant non-small cell lung cancer (NSCLC) [1] - The company has also recently submitted two additional Phase III registration clinical trials for different types of lung cancer [1] Group 2: Research and Development Pipeline - According to a recent report from Guoyuan International, the company's research pipeline is continuously expanding, enhancing its risk resistance capabilities [1] - The clinical efficacy data for the CD47CD20 dual antibody (IMM0306) is reported to be excellent, with potential to become a significant drug in the autoimmune field [1] - Yiming Oncology is recognized as a global innovator in CD47 fusion proteins, with a rich pipeline and broad application prospects in oncology and autoimmune diseases [1]
宜明昂科-B再涨超6% 已向CDE提交IMM2510的III期临床试验申请